Drug intelligence / Profile preview

NTI-1309

Development stage: Unknown
Lead developer: Lantheus
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NTI-1309 is an innovative PET oncology imaging agent that targets fibroblast activation protein (FAP). FAP is highly expressed in the tumor microenvironment, specifically in tumor-associated fibroblasts (TAFs) that are believed to modulate tumor progression and immune response. Developed by Noria Therapeutics and acquired by Lantheus Holdings, NTI-1309 is designed to provide broad imaging applicability across various cancer types. It is currently in early clinical development (Phase 1) to evaluate its potential as a diagnostic tool and biomarker for oncology drug development programs.

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on NTI-1309.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTI-1309.

Explore the full profile